Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A., and its Mexican affiliate, ...

Epigenetic therapies are offering a more targeted way to treat some lymphomas by changing how genes are turned on or off ...

Hodgkin lymphoma (HL) is a treatable cancer with an incidence peak in adolescent and young adult years. Treatment strategies have been developed to balance the intensity of therapy needed to maintain ...

Recent advances in cancer treatment are transforming the outlook for patients with lymphoma, offering renewed hope where options were once limited. According to Dr. Rahul Bhargava, one of India''s ...

Hodgkin lymphoma and primary mediastinal B-cell lymphoma are two aggressive blood cancers that affect young people between their late teens and mid-30s, a group often referred to as Adolescents and ...

Follicular lymphoma, a common and usually slow-growing type of non-Hodgkin lymphoma (NHL), has long been deemed incurable: Though the disease responds well to initial treatment, oncologists tell ...

Stage 1 mixed cellularity Hodgkin lymphoma is often highly treatable, and many patients achieve long-term remission after ...

Stage 4 lymphoma is a cancer of white blood cells called lymphocytes that has spread outside the lymph nodes to other parts of the body. While this is an advanced stage, treatment options are ...

Optimally positioning CD19-directed therapies in the follicular lymphoma treatment sequence requires consideration of both efficacy and the risk of sacrificing future options. The introduction of CD19 ...

• Cancer-related fatigue (CRF) is a prevalent issue for individuals undergoing lymphoma treatment, stemming from the cancer itself, the emotional and physical toll, and the side effects of treatment. ...